CLAIMS

1. A compound of formula (Ig), formula (Ih), formula (Ij), or formula (Ik), or a pharmaceutically acceptable salt thereof:



(Ig);



(Ih);



(Ij);



(Ik);

wherein:

 represents  or  ; and

X_C represents CH or N;

 represents  ;

J represents $–CH_2–$or –C(O)–;

K represents a bond, –O–, or –NH–;

L^D represents $–CH_2–$,–CH(OH)–,

or a bond;

R^A, independently for each occurrence, represents H, optionally substituted alkoxy, or optionally substituted (heteroaryl)alkoxy;

R^B, independently for each occurrence, represents H, oxo, or is optionally substituted alkyl, aryl, cycloalkyl, (cycloalkyl)alkyl, or heterocycloalkyl;

R^C, independently for each occurrence, represents H, halo, -OH, or is optionally substituted alkoxy;

R^x is H or OH;

R^D, independently for each occurrence, represents H, or is optionally substituted alkyl or alkoxy;

R^1 represents H; and

n and p are each independently 0, 1, or 2.

2. The compound of claim 1, having the structure of formula (Ij) or (Ik):



(Ij); or



(Ik).

3. The compound of claim 1 or 2, wherein



represents



.

4. The compound of any one of claims 1-3, wherein R^C represents H or alkoxy (e.g., methoxy).

5. The compound of any one of claims 1-4, wherein –J–K– represents $–CH_2$-O– or –C(O)-NH–.

6. The compound of any one of claims 1-5, wherein L^D represents a bond.

7. The compound of any one of claims 1-6, wherein L^D represents $–CH_2–$.

8. The compound of any one of claims 1-7, wherein R^D, independently for each occurrence, represents H, unsubstituted alkyl, or unsubstituted alkoxy.

9. The compound of any one of claims 1-8, wherein R^B, independently for each occurrence, represents H, alkyl, cycloalkyl, (cycloalkyl)alkyl, or heterocycloalkyl.

10. The compound of any one of claims 1-9, wherein R^A, independently for each occurrence, represents H.

11. The compound of claim 1, selected from the following table:

	
	

	
	
	
	
	

	
	
	
	

	
	
	
	
	

	
	
	
	

.

12. A pharmaceutical composition, comprising a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

13. Use of a compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease or condition characterized by aberrant kallikrein activity;
wherein the disease or condition characterized by aberrant kallikrein activity is selected from the group consisting of Netherton Syndrome, hypersensitivity of the immune system (atopy), hyper IgE syndrome, allergies (including allergies to food and airborne agents), asthma, allergic asthma, chronic inflammation, rhinitis, conjunctivitis, angioedema, eosinophilia, eosinophilic esophagitis, growth delay, failure to thrive, trichorrhexis invaginata (TI), respiratory tract infections, systemic infections, gastrointestinal disorders, ovarian cancer, breast cancer, prostate cancer, bladder cancer, cervical cancer, glioblastoma multiforme, and neuroblastoma.

14. The use of claim 13, wherein the disease or condition characterized by aberrant kallikrein activity is Netherton Syndrome.

15. The use of claim 13, wherein the disease or condition characterized by aberrant kallikrein activity is selected from the group consisting of hypersensitivity of the immune system (atopy), hyper IgE syndrome, allergies (including allergies to food and airborne agents), asthma, allergic asthma, chronic inflammation, rhinitis, conjunctivitis, angioedema, eosinophilia, eosinophilic esophagitis, growth delay, failure to thrive, trichorrhexis invaginata (TI), respiratory tract infections, systemic infections, and gastrointestinal disorders.

16. The use of claim 13, wherein the disease or condition characterized by aberrant kallikrein activity is selected from the group consisting of ovarian cancer, breast cancer, prostate cancer, bladder cancer, cervical cancer, glioblastoma multiforme, and neuroblastoma.

17. A compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a disease or condition characterized by aberrant kallikrein activity; wherein the disease or condition characterized by aberrant kallikrein activity is selected from the group consisting of Netherton Syndrome, hypersensitivity of the immune system (atopy), hyper IgE syndrome, allergies (including allergies to food and airborne agents), asthma, allergic asthma, chronic inflammation, rhinitis, conjunctivitis, angioedema, eosinophilia, eosinophilic esophagitis, growth delay, failure to thrive, trichorrhexis invaginata (TI), respiratory tract infections, systemic infections, gastrointestinal disorders, ovarian cancer, breast cancer, prostate cancer, bladder cancer, cervical cancer, glioblastoma multiforme, and neuroblastoma.